264 related articles for article (PubMed ID: 23530423)
1. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
[TBL] [Abstract][Full Text] [Related]
4. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
[TBL] [Abstract][Full Text] [Related]
5. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
Ambrose CS; Chen X; Kumar VR
Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.
Chang SG; Park MS; Yu JE
J Korean Med Sci; 2010 Feb; 25(2):251-6. PubMed ID: 20119579
[TBL] [Abstract][Full Text] [Related]
7. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
[TBL] [Abstract][Full Text] [Related]
8. [Humanized respiratory syncytial virus monoclonal antibody].
Tsutsumi H
Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
10. Palivizumab: a debate about funding.
Fitzgerald DA; Isaacs D; Tobin B
J Paediatr Child Health; 2012 May; 48(5):373-7. PubMed ID: 22296413
[TBL] [Abstract][Full Text] [Related]
11. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
Han YM; Seo HJ; Choi SH; Jung YJ; Ahn SY; Yoo HS; Sung SI; Shim JW; Lee YK; Ko SY; Shin SM; Hwang JH; Lee JH; Choi BM; Kim ES; Jeon JH; Kim SS; Chang YS; Park WS
J Korean Med Sci; 2015 Jul; 30(7):924-31. PubMed ID: 26130956
[TBL] [Abstract][Full Text] [Related]
12. RSV immunoprophylaxis: does the benefit justify the cost?
Meissner HC; Kimberlin DW
Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
[No Abstract] [Full Text] [Related]
13. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.
Abraha HY; Lanctôt KL; Paes B
Expert Rev Respir Med; 2015; 9(6):779-99. PubMed ID: 26457970
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
15. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Warren A; Langley JM; Thomas W; Scott J
Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
[TBL] [Abstract][Full Text] [Related]
17. [Indications and prescription modalities of palivizumab in neonates].
Guillois B
Arch Pediatr; 2007 Sep; 14 Suppl 1():S16-23. PubMed ID: 17939952
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
19. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
[No Abstract] [Full Text] [Related]
[Next] [New Search]